BACKGROUND AND AIMS

Psoriasis is an immune-mediated disease affecting primarily the skin and joints, but which also has systemic implications. There are assumptions about a common genetic background between psoriasis and cardiovascular diseases. This narrative review aims to provide an overview of the existing data regarding the IL-23 rs2066808, IL-23R rs2201841, IL-17RA rs4819554, and IL-17A rs2275913 polymorphisms and their link to psoriasis and cardiovascular diseases.

METHODS

PubMed, Web of Science, Scopus, and "SNPedia" searches were conducted to identify the relevant studies between 2007 and 2025 that investigated the association between psoriasis, cardiovascular diseases, and the IL-23 rs2066808, IL-23R rs2201841, IL-17RA rs4819554, and IL17A rs2275913 polymorphisms.

RESULTS

The existing data are conflicting. The polymorphisms could be implicated in psoriasis onset, disease susceptibility, and treatment response. Some of them are also linked to coronary artery disease. Contradictory data could result from the heterogeneity of the population included in the studies and the laboratory techniques used for polymorphism determination.

CONCLUSION

The interplay between IL-17, IL-23, and genetic polymorphisms illustrates a complex landscape in psoriasis and its associated comorbidities. More standardized case-control studies are needed to confirm this hypothesis. Moreover, extensive studies in diverse populations would be important to clarify these relationships and the potential implications for treatment and management.